Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPenumbra Inc

Penumbra Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
320.02 USD 0.00(0%)
Last update at 2026-11-03T21:00:00Z
VOLUME
425187
Market Cap
12542.77M
P/E
78.05

Momentum Score

…

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
319.93
Low
322.11
High
52 Week Price Range
221.26
Low
362.41
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
320.02
Dividend Yield
-
Revenue TTM
1504.87M
Revenue Per Share
38.36
Gross Profit TTM
1020.90M
Debt / Equity
0.15
ROE
11.37%
Net Debt
32.80M
ROCE
12.56%
Diluted EPS TTM
4.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 205.12M 20.87M 79.65M 3.89M -10.50M
Minority interest - - 0.00M 0.00M 2.66M
Net income 177.69M 14.01M 90.95M -2.00M 2.62M
Selling general administrative 663.42M 572.39M 505.25M 449.72M 378.33M
Selling and marketing expenses - 1.60M 1.20M - -
Gross profit 942.44M 755.00M 682.64M 535.21M 475.38M
Reconciled depreciation 17.47M 23.70M 27.26M 24.32M 16.41M
Ebit 206.44M 22.29M 81.39M -18.24M -23.91M
Ebitda 223.91M 45.99M 108.65M 6.08M -7.50M
Depreciation and amortization 17.47M 23.70M 27.26M 24.32M 16.41M
Non operating income net other - - - -2.33M -3.94M
Operating income 189.25M 86.22M 73.55M -18.24M -7.50M
Other operating expenses 1214.42M 1108.39M 984.97M 841.05M 755.09M
Interest expense 1.31M 1.42M 1.74M 0.14M 16.07M
Tax provision 27.44M 6.86M -11.30M 5.89M -13.12M
Interest income 16.29M 13.69M 6.83M 0.14M 0.94M
Net interest income 14.98M 12.27M 5.09M 0.14M 0.94M
Income tax expense 27.44M 6.86M -11.30M 5.89M -13.12M
Total revenue 1403.66M 1194.62M 1058.52M 847.13M 747.59M
Total operating expenses 753.19M 668.77M 609.09M 529.12M 482.88M
Cost of revenue 461.23M 439.62M 375.88M 311.93M 272.21M
Total other income expense net 15.88M -65.36M 6.10M 22.13M -3.00M
Net income from continuing ops 177.69M 14.01M 90.95M -2.00M 2.62M
Net income applicable to common shares 177.69M 14.01M 90.95M -2.00M 5.28M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1826.52M 1533.18M 1556.31M 1370.89M 1244.25M
Intangible assets 6.83M 7.20M 63.16M 81.16M 90.62M
Other current assets 50.30M 36.59M 36.42M 30.28M 29.16M
Total liab 398.92M 382.25M 377.36M 372.03M 290.32M
Total stockholder equity 1427.60M 1150.93M 1178.94M 998.86M 953.93M
Deferred long term liab - - - 5.10M 5.80M
Other current liab 132.16M 111.49M 103.57M 97.14M 99.80M
Common stock 0.04M 0.04M 0.04M 0.04M 0.04M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.04M
Retained earnings 237.69M 60.00M 134.86M 43.90M 45.91M
Other liab - - - 3.28M 3.56M
Good will 166.75M 165.83M 166.27M 166.05M 166.39M
Other assets 119.90M 141.27M 111.04M 77.01M 78.68M
Cash 186.90M 324.40M 167.49M 69.86M 59.38M
Cash and equivalents 186.90M 324.40M 167.49M 69.86M 59.38M
Total current liabilities 183.13M 158.34M 151.14M 144.93M 123.20M
Current deferred revenue - 0.94M 6.99M 9.16M -
Net debt 32.80M -101.02M 66.86M 165.91M 114.17M
Short term debt 16.23M 14.59M 13.43M 11.95M 9.98M
Short long term debt total 219.70M 223.39M 234.34M 235.77M 173.55M
Other stockholder equity 1185.53M 1096.73M 1047.20M 963.04M 910.61M
Property plant equipment 317.00M 268.45M 292.54M 290.97M 227.09M
Total current assets 1216.68M 951.12M 915.40M 755.70M 681.47M
Net tangible assets - - - 751.65M 696.92M
Short term investments 357.92M 15.73M 121.70M 118.17M 195.50M
Net receivables 190.02M 167.67M 201.77M 203.38M 133.94M
Inventory 431.55M 406.74M 388.02M 334.01M 263.50M
Accounts payable 34.74M 31.33M 27.16M 26.68M 13.42M
Accumulated other comprehensive income 4.35M -5.84M -3.15M -8.12M -2.63M
Common stock total equity - - - 0.04M 0.04M
Retained earnings total equity - - - 43.90M 45.91M
Non currrent assets other 40.72M 40.94M 25.88M 12.79M 12.98M
Non current assets total 609.84M 582.06M 640.90M 615.19M 562.78M
Capital lease obligations 219.70M 223.39M 234.34M 235.77M 173.55M
Long term debt total 20.71M 21.73M 23.68M 24.86M 26.52M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -340.86M 77.62M -31.72M 74.09M -3.07M
Change to liabilities - - - 23.93M -1.56M
Total cashflows from investing activities -404.59M 77.62M -16.08M 54.79M -21.73M
Net borrowings -2.48M -2.28M -1.98M -1.75M -1.45M
Total cash from financing activities 26.53M -87.01M 16.20M 11.62M 0.84M
Change to operating activities - - - 9.57M 7.75M
Net income 177.69M 14.01M 90.95M -2.00M 2.62M
Change in cash -137.51M 156.92M 97.63M 10.48M -10.29M
Begin period cash flow 324.40M 167.49M 69.86M 59.38M 69.67M
End period cash flow 186.90M 324.40M 167.49M 69.86M 59.38M
Total cash from operating activities 238.66M 168.48M 97.33M -55.66M 9.50M
Issuance of capital stock - - - 0.00M 0.00M
Depreciation 17.47M 23.70M 30.61M 24.32M 16.41M
Other cashflows from investing activities -340.86M 1.10M -0.50M 74.09M -0.40M
Change to inventory -26.48M -65.66M -67.71M -74.63M -51.55M
Change to account receivables -19.51M 26.60M -0.27M -69.86M -21.34M
Sale purchase of stock 31.82M -100.39M -2.07M 21.55M 18.37M
Other cashflows from financing activities -2.80M -1.52M -2.23M -0.39M -11.42M
Change to netincome - - - 43.55M 57.18M
Capital expenditures 63.73M 21.18M 15.21M 19.30M 21.18M
Change receivables - - - -69.86M -21.34M
Cash flows other operating - - - -0.97M -9.32M
Cash and cash equivalents changes - - - 10.75M -11.40M
Change in working capital -42.72M -23.78M -79.08M -121.80M -70.42M
Stock based compensation 59.21M 46.16M 50.52M 37.38M 65.76M
Other non cash items 5.97M 124.72M 73.92M 4.98M 9.22M
Free cash flow 174.93M 147.30M 82.12M -74.96M -11.68M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PEN
Penumbra Inc		 -
-%		 320.02 78.05 55.56 8.33 8.19 8.04 54.42
ABT
Abbott Laboratories		 -
-%		 109.40 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -0.41
0.41%		 98.88 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 3.74
1.22%		 310.55 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.66
1.38%		 48.35 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

One Penumbra Place, Alameda, CA, United States, 94502

510 748 3200

https://www.penumbrainc.com

4700

Name Title Year Born
Mr. Adam Elsesser Co-Founder, Chairman, Pres & CEO 1962
Dr. Arani Bose M.D. Co-Founder & Director 1962
Ms. Maggie S. Yuen Chief Financial Officer 1972
Mr. Lambert Shiu Chief Accounting Officer 1980
Ms. Johanna Roberts Exec. VP, Gen. Counsel & Sec. 1972
Ms. Lynn Rothman Exec. VP & Chief Bus. Officer 1961
Mr. Ben Sorci Exec. VP of Operations NA
Mr. Pankaj Tiwari Exec. VP & Chief Information Officer NA
Ms. Jee Hamlyn-Harris Investor Relations Officer NA
Ms. Shruthi Narayan Director of Marketing - Vascular NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…